Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT4 | P35916 | 2/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CASR | P41180 | 10/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | FES | P07332 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | MARK3 | P27448 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | CLK2 | P49760 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5557503 | 0.81 | EPHX2 (0.53) | FLT4CDK2EPHX2CYP2C9CYP2C19 | |
| SCHEMBL5557494 | 0.76 | FES (0.76) | FLT4EPHX2CYP2C9CYP2C19CASR | |
| SCHEMBL5557434 | 0.75 | LMNA (0.54) | FLT4CDK2LMNA | |
| SCHEMBL14559615 | 0.72 | CASR (0.58) | EPHX2CASR | |
| SCHEMBL15061601 | 0.69 | LMNA (0.54) | FLT4CDK2LMNA | |
| SCHEMBL12913969 | 0.69 | KDM1A (0.73) | EPHX2CASR | |
| SCHEMBL8775822 | 0.69 | TBXAS1 (0.55) | EPHX2CYP2C9CYP2C19CASRTBXAS1 | |
| SCHEMBL22170087 | 0.69 | CDK2 (0.69) | FLT4CDK2KEAP1NFE2L2 | |
| SCHEMBL4617484 | 0.69 | EPHX2 (1.00) | EPHX2LMNATBXAS1 | |
| SCHEMBL12913677 | 0.68 | KDM1A (0.70) | EPHX2CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1154998-B1 | INHIBITORS OF CELLULAR NIACINAMIDE MONONUCLEOTIDE FORMATION AND THEIR USE IN CANCER THERAPY | ASTELLAS DEUTSCHLAND GMBH (DE) | 2007-09-26 | — | — | EP | claimed |
| US-6506572-B2 | Inhibitor of niacinamide phosphoribosyl transferase (NAPRT) | KLINGE PHARMA GMBH (DE) | 2003-01-14 | — | — | US | claimed |
| JP-2002537380-A | — | — | 2002-11-05 | — | — | JP | claimed |
| US-20020160968-A1 | Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy | KLINGE PHARMA GMBH | 2002-10-31 | — | — | US | claimed |
| EP-1154998-A1 | INHIBITORS OF CELLULAR NIACINAMIDE MONONUCLEOTIDE FORMATION AND THEIR USE IN CANCER THERAPY | Klinge Pharma GmbH (DE) | 2001-11-21 | — | — | EP | claimed |
| WO-2000050399-A1 | INHIBITORS OF CELLULAR NIACINAMIDE MONONUCLEOTIDE FORMATION AND THEIR USE IN CANCER THERAPY | KLINGE PHARMA GMBH (DE) | 2000-08-31 | — | — | WO | claimed |
| EP-1031564-A1 | Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy | Klinge Pharma GmbH (DE) | 2000-08-30 | — | — | EP | claimed |
| EP-1154998-B1 | INHIBITORS OF CELLULAR NIACINAMIDE MONONUCLEOTIDE FORMATION AND THEIR USE IN CANCER THERAPY | ASTELLAS DEUTSCHLAND GMBH (DE) | 2007-09-26 | — | — | EP | disclosed |
| EP-1816124-A2 | Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy | Astellas Deutschland GmbH (DE) | 2007-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160968-A1 | Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy | NAMPT, NAPRT, NNT | FLT4 4277/4885CDK2 720/4885EPHX2 2339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.